Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E7.32 EPS (ttm)11.92 Insider Own0.40% Shs Outstand1.44B Perf Week5.49%
Market Cap125.74B Forward P/E7.00 EPS next Y12.47 Insider Trans-22.04% Shs Float1.42B Perf Month-9.54%
Income18.11B PEG0.88 EPS next Q3.08 Inst Own82.70% Short Float1.63% Perf Quarter-19.12%
Sales32.64B P/S3.85 EPS this Y62.00% Inst Trans0.28% Short Ratio2.13 Perf Half Y-24.54%
Book/sh13.31 P/B6.56 EPS next Y2.10% ROA40.20% Target Price118.63 Perf Year-8.89%
Cash/sh18.19 P/C4.80 EPS next 5Y8.33% ROE103.50% 52W Range81.89 - 122.36 Perf YTD-13.78%
Dividend1.72 P/FCF- EPS past 5Y48.30% ROI97.50% 52W High-27.88% Beta1.04
Dividend %1.97% Quick Ratio3.20 Sales past 5Y32.60% Gross Margin87.70% 52W Low7.77% ATR3.26
Employees7000 Current Ratio3.40 Sales Q/Q16.30% Oper. Margin68.00% RSI (14)44.86 Volatility3.73% 3.74%
OptionableYes Debt/Eq0.00 EPS Q/Q45.90% Profit Margin55.50% Rel Volume1.11 Prev Close87.25
ShortableYes LT Debt/Eq0.00 EarningsFeb 02 AMC Payout10.40% Avg Volume10.86M Price88.25
Recom2.00 SMA20-0.63% SMA50-8.63% SMA200-16.57% Volume9,894,301 Change1.15%
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-20-15Reiterated Oppenheimer Outperform $120 → $124
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-15Initiated Jefferies Hold
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-29-15Reiterated Piper Jaffray Overweight $131 → $134
Jul-29-15Reiterated Oppenheimer Outperform $86 → $120
Jul-29-15Reiterated Needham Buy $120 → $125
Jul-29-15Reiterated Maxim Group Buy $127 → $129
Jul-29-15Reiterated Deutsche Bank Buy $125 → $135
Jul-29-15Reiterated Barclays Overweight $125 → $130
Jul-24-15Reiterated Piper Jaffray Overweight $120 → $131
Jun-23-15Reiterated Argus Buy $130 → $150
Feb-10-16 02:18PM  Gilead (GILD) Stock Gains, Barclays Sees Upside Potential for Hep-C Drugs at TheStreet
01:55PM  The Secrets Out: This Biotech Just Stunned the World
12:59PM  Gilead Sciences: A Good Set Up for Earnings Beats? at Barrons.com
08:40AM  Major Biotech Short Interest Continues to Be Mixed at 24/7 Wall St.
08:12AM  What to Expect from Gilead Sciences, Inc.'s New CEO at Motley Fool
Feb-09-16 09:23PM  3 Biotech Stocks to Buy in a Market Crash at Motley Fool
04:07PM  Icahn, Gilead, GE Lead Top Insider Trades Of The Week
01:48PM  Biotech ETFs Slide as Stocks Report Mixed Q4 Results
01:02PM  What Investors Can Expect from Healthcare Sector Companies
08:29AM  Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck at Motley Fool
08:05AM  Rebound For Big Biotech ETF Will Require Some Patience
01:05AM  [$$] Overheard: Biotech Waiting Game Still Paying Off for Gilead at The Wall Street Journal
Feb-08-16 09:33PM  [$$] OVERHEARD at The Wall Street Journal
05:00PM  Gilead Sciences to Participate in Two Upcoming Investor Conferences Business Wire
03:50PM  Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA
02:33PM  Biotech Waiting Game Still Paying Off For Gilead at The Wall Street Journal
02:19PM  Why GoPro, Microsoft, Twitter and Two Other Stocks Are in Spotlight Today at Insider Monkey
01:23PM  Will Gilead Sciences, Inc. Continue to Dominate HIV Treatment? at Motley Fool
10:53AM  How To Invest In An Aging World With The 'Live Long & Prosper' ETF
09:26AM  Why Gilead Sciences (GILD) Stock May Advance Today at TheStreet
12:55AM  [$$] Punishing the Cure Makers Wont End Cancer at The Wall Street Journal
Feb-07-16 09:38PM  Celgene, Gilead Sciences shares could rise 30 percent: Barron's
07:11AM  Is Gilead Sciences Finally Nearing a Bottom? at Motley Fool
Feb-06-16 10:50AM  How Analysts Value Gilead Now After Earnings at 24/7 Wall St.
09:41AM  Grading Gilead Sciences' Performance in 2015 at Motley Fool
09:40AM  1 Company Gilead Sciences Should Consider Buying Right Now at Motley Fool
12:01AM  [$$] Celgene and Gilead: Two Drugmakers, 30% Upside at Barrons.com
Feb-05-16 06:40PM  3 trades to watch as stock pain continues at CNBC
05:00PM  3 safe trades in today's market
03:40PM  Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again? at Motley Fool
03:16PM  Gilead's Glory Days Are Over -- Here's Why You Should Dump the Stock at TheStreet
12:37PM  Gilead Sciences (GILD) Stock Gets Outperform Rating at Leerink at TheStreet
12:25PM  Shkreli theatrical display misses core biotech pricing issues
11:30AM  Gilead Sciences: Why Slowing Hep-C Sales Don't Matter at Barrons.com
08:02AM  Strong Dollar Pounds S&P 500 Into Earnings Recession
07:39AM  5 Stocks We're Buying Again at Motley Fool
Feb-04-16 04:49PM  4 Can't-Miss Numbers From GlaxoSmithKline's Fourth-Quarter Results at Motley Fool
03:40PM  Why Achillion Pharmaceuticals Shares Crashed 37% in January at Motley Fool
02:29PM  Its Time to Buy This Biotech Gem
12:39PM  25 Companies That Could Still Buy Back Mountains Of Stock
10:31AM  Gilead Sciences, Inc. Earnings Analysis: 2015 By the Numbers
10:29AM  Why M&A Delay Can Spell Disaster for Gilead Stock
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
08:59AM  Why Did Biotech Fall Off a Cliff in January? at Motley Fool
08:05AM  Momentum, Strategy within Today's Market - Analyst Notes on Gilead Sciences, Schlumberger, Royal Caribbean Cruises and Allergan Accesswire
Feb-03-16 07:02PM  Cramer: Machines Can Take More Pain, So the Market Rout Lasts Longer
04:35PM  Gilead's Stock is on Sale: Should You Buy?
04:07PM  GILEAD SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers
03:43PM  [$$] Merck Revenue and Profit Fall at The Wall Street Journal
02:44PM  Forget Gilead Sciences: These Stocks Doubled Last Year at Motley Fool
02:25PM  Gilead Needs to Go Shopping at Bloomberg
02:24PM  Whats Driving Oclaro, Gilead, Eaton, Boot Barn Holdings & Viavi Higher on Wednesday? at Insider Monkey
02:11PM  Instant Analysis: Gilead Sciences Raises Its Dividend 10% at Motley Fool
01:31PM  Comcast spent tons of money buying back shares, but earnings still fell short at MarketWatch
01:30PM  Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over
01:05PM  Illumina Brings More Pain To Battered Biotech ETFs; Gold Hits High
12:16PM  International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results at Motley Fool
12:00PM  Gilead (GILD) Stock Gains as Analysts Discuss Earnings Results at TheStreet
10:42AM  Stocks Slump as Services Sector Slows to 2014 Low at TheStreet
10:37AM  Ronnie Moas Initiates Gilead At Buy; Models Show It's A Top 10 S&P Stock
10:32AM  Chipotle drops as probe widens; Amazon report hits Barnes & Noble; Gilead up on earnings beat
10:02AM  The Real Risks of Gileads Stock
09:53AM  Gilead Sciences: 'For Value Investors Who Seek Contrarian Ideas' at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Yahoo, Chipotle, Gilead Sciences and Match Group
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
09:30AM  The Zacks Analyst Blog Highlights: Darden Restaurants, KLA-Tencor, Motorola Solutions, Gilead Sciences and NVIDIA
09:00AM  Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
08:10AM  Insight into the Performance of Interferon and Other Products
08:02AM  Coverage initiated on Gilead Sciences by Standpoint Research
07:58AM  Early movers: CMCSA, GM, MRK, MRVL, BDX & more at CNBC
07:31AM  Merck beats 4Q profit forecast, misses Street view on sales
06:00AM  Gilead: Most Valuable Biotech Asset in Market is Our Own Stock at TheStreet
12:13AM  Edited Transcript of GILD earnings conference call or presentation 2-Feb-16 9:30pm GMT
12:00AM  Seven $1 billion-plus drugs seen reaching market in 2016 Reuters
Feb-02-16 07:03PM  Gilead Sciences beats 4th-quarter forecasts on higher sales
06:59PM  Yahoo Leads 5 Stocks Moving Late On Earnings Reports
06:35PM  Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street
06:31PM  Gilead hepatitis C drug sales beat estimates, but growth stalls
06:27PM  Q4 Earnings Train Keeps Chugging: Yahoo (YHOO), Chipotle (CMG) & More
05:59PM  [$$] Gilead Hepatitis C Drugs Beat Sales Views at The Wall Street Journal
05:51PM  Gilead: Reading the Biotech M&A Tea Leaves at The Wall Street Journal
05:32PM  Gilead Sciences (GILD) Beats Earnings and Revenue Estimates
04:45PM  Earnings Recap For February 2
04:33PM  Gilead: 4Q EPS, Revenue Beat at Barrons.com
04:31PM  Gilead Rises on Solid HCV Sales and Earnings Beat
04:30PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today
04:24PM  Gilead (GILD) Stock Gaining in After-Hours Trading Following Q4 Earnings Results at TheStreet
04:20PM  Gilead hepatitis C drug sales edge past Wall Street estimates
04:15PM  Gilead Sciences shares rise on earnings, revenue beat at MarketWatch
04:05PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:04PM  Tesla Hits 52-Week Low at 24/7 Wall St.
04:04PM  Gilead Says This Years Sales Will Fall Short of Estimates at Bloomberg
04:01PM  Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs Business Wire
04:00PM  Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results Business Wire
03:39PM  Health care analyst: How to play the current biotech market ahead of earnings
12:55PM  What Expect From Gilead Earnings
12:20PM  Why Gilead Sciences Shares Tumbled 18% in January at Motley Fool
12:07PM  Gilead Sciences: It's Almost Earnings Time at Barrons.com
11:19AM  Start the New Year off Right with 3 Best Biotech Stocks at Motley Fool
10:44AM  5 Top-Rated S&P 500 Dividend Stocks to Buy in February
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has a strategic partnership with WuXi PharmaTech (Cayman) Inc.; collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos; and a partnership with Gilead Sciences Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise14.50150,0002,175,3754,098,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise24.305,000121,475140,422Oct 05 02:13 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale97.287,000680,930133,422Oct 05 02:13 PM
MARTIN JOHN CChairman and CEOOct 01Sale97.48150,00014,622,2893,948,066Oct 05 01:28 PM
Carter Paul RutherfordEVP Commercial OpsOct 01Sale98.592,000197,18048,783Oct 05 04:26 PM
Cogan John FrancisDirectorSep 15Option Exercise20.7115,000310,57559,309Sep 17 03:54 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Option Exercise23.6070,0001,652,000235,168Sep 17 04:26 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Option Exercise24.305,000121,475140,422Sep 17 03:55 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Sale110.005,000550,000135,422Sep 17 03:55 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Sale110.7070,0007,749,195165,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Sale110.0015,0001,650,00044,309Sep 17 03:54 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise14.50100,0001,450,2501,129,108Sep 10 02:57 PM
MILLIGAN JOHN FPresident and COOSep 08Sale103.39100,00010,338,7301,029,108Sep 10 02:57 PM
Washington Robin LEVP, CFOSep 02Sale102.206,250638,77894,296Sep 03 03:07 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Option Exercise24.2210,000242,208147,422Sep 03 03:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Sale102.7512,0001,233,008135,422Sep 03 03:06 PM
WILSON GAYLE EDirectorAug 28Option Exercise20.7180,0001,656,400122,769Aug 31 06:17 PM
WILSON GAYLE EDirectorAug 28Sale106.9621,0002,246,160101,769Aug 31 06:17 PM
MARTIN JOHN CChairman and CEOAug 25Sale105.17133,21314,009,8720Aug 26 05:51 PM
Cogan John FrancisDirectorAug 03Option Exercise20.7115,000310,57559,309Aug 04 05:01 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Option Exercise23.7615,000356,325154,422Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Option Exercise14.50150,0002,175,3754,364,492Aug 04 05:07 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Option Exercise26.995,000134,95053,783Aug 04 05:08 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Sale119.185,000595,92048,783Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Sale119.18150,00017,876,6194,214,492Aug 04 05:07 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Sale119.1117,0002,024,870137,422Aug 04 05:08 PM
Cogan John FrancisDirectorAug 03Sale120.0015,0001,800,00044,309Aug 04 05:01 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500050,132Aug 04 05:00 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Option Exercise21.5870,0001,510,250235,168Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Sale118.2066,2617,832,152168,907Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 07Sale119.393,739446,400165,168Jul 17 03:57 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise26.993,00080,97050,632Jul 06 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.7615,000356,325156,422Jul 06 04:01 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise14.50150,0002,175,3754,364,492Jul 06 04:02 PM
MARTIN JOHN CChairman and CEOJul 01Sale116.46150,00017,469,6614,214,492Jul 06 04:02 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale116.7317,0001,984,446139,422Jul 06 04:01 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale118.243,000354,72947,632Jul 06 04:00 PM
Cogan John FrancisDirectorJun 26Option Exercise14.3412,000172,08056,309Jun 30 07:32 PM
Cogan John FrancisDirectorJun 26Sale120.1327,0003,243,42144,309Jun 30 07:32 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Option Exercise26.9910,000269,90057,632Jun 22 04:17 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Sale120.0010,0001,200,02547,632Jun 22 04:17 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Option Exercise21.5870,0001,510,250235,168Jun 17 07:25 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Sale117.6770,0008,237,002165,168Jun 17 07:25 PM
MILLIGAN JOHN FPresident and COOJun 08Option Exercise14.50100,0001,450,2501,129,108Jun 10 01:03 PM
MILLIGAN JOHN FPresident and COOJun 08Sale114.05100,00011,405,4131,029,108Jun 10 01:03 PM
MARTIN JOHN CChairman and CEOJun 01Option Exercise14.50150,0002,175,3754,405,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Option Exercise23.7115,000355,647158,422Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise34.713,000104,12050,632Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale113.093,000339,27847,632Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Sale113.6417,0001,931,891141,422Jun 03 06:07 PM
MARTIN JOHN CChairman and CEOJun 01Sale113.95150,00017,092,3444,255,876Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Option Exercise67.786,000406,68753,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Option Exercise21.3470,0001,493,550235,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Option Exercise19.2025,000479,947168,422May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Sale110.0125,0002,750,210143,422May 19 07:25 PM